Lexicon Pharmaceuticals
Home
Contact Us
Site Map
About Us
About Us Home
Management Team
Board of Directors
Development Team
Locations
Contact Us
History
Pipeline
Drug Pipeline Home
Our Goal
Therapeutic Areas
Drug Development Team
Clinical Trials
Publications
Discovery
Discovery Home
Discovery Process
Technology
Genome5000
Medicinal Chemistry
Biotherapeutics
Patents
Academic Access
Technology Licensing
Alliances
Alliances Home
Current Alliances
Technology Licensing
Careers
Careers Home
Opportunities
Our Culture
Benefits
Community Involvement
The Woodlands
Princeton
Awards and Recognition
News
News Home
Media Inquiries
Investors
Investors Home
Media
Events
Stock Quote
SEC Filings
Annual Reports
Corporate Governance
Request Information
News Home
Media Inquiries
Subscribe
Press Releases
Filter
Display #
5
10
15
20
25
30
50
100
All
01/29/2007
Lexicon Advances LX6171 for Cognitive Disorders into Phase 1b Clinical Trial
01/29/2007
Lexicon Genetics Changing Name, Refocusing Business to Achieve Goal of Advancing Ten Drug Candidates into Human Clinical Trials by 2010
01/23/2007
Lexicon Genetics Initiates Clinical Trials of LX1031 for Irritable Bowel Syndrome
01/03/2007
Lexicon Genetics to Present at the 25th Annual JPMorgan Healthcare Conference
12/07/2006
Lexicon Genetics to Present at RBC Capital Markets Healthcare Conference
12/04/2006
Lexicon Genetics Files Investigational New Drug Application for LX1031 in Irritable Bowel Syndrome
11/20/2006
Lexicon Genetics to Webcast Presentations at Upcoming Lazard and Piper Jaffray Investor Conferences
11/01/2006
Lexicon Genetics to Present at Rodman & Renshaw 8th Annual Healthcare Conference
10/30/2006
Lexicon Genetics Reports 2006 Third Quarter Financial Results
10/23/2006
Lexicon Genetics to Report Third Quarter 2006 Financial Results on October 31, 2006
«
Start
Prev
1
2
3
4
5
6
7
8
9
10
Next
End
»
Page 7 of 32